Proepithelin is an autocrine growth factor for bladder cancer

Francesca Lovat1,4, Alessandro Bitto1,4, Shi-Qiong Xu1, Matteo Fassan1, Silvia Goldoni2, David Metalli1, Vera Wubah1, Peter McCue2, Ginette Serrero3,4, Leonard G.Gomella1,5, Raffaele Baffa1,7, Renato V.Loizzo6,8 and Andrea Morroni1,5,*

1Department of Urology and Department of Pathology, Anatomy and Cell Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. 2A&G Pharmaceutical Inc., Columbia, MD 21045, USA. 3Program in Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA. 4Endocrine Mechanisms and Hormone Action Program and 5Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. 5Present address: Medimmune, One Medimmune Way, Gaithersburg, MD 20878, USA. 6Program in Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA. 7Present address: Medimmune, One Medimmune Way, Gaithersburg, MD 20878, USA.

To whom correspondence should be addressed. Department of Urology, Endocrine Mechanisms and Hormone Action Program, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Bluemle Life Sciences Building, Room 620, Philadelphia, PA 19107, USA. Tel: +1 215 503 4519; Fax: +1 215 923 0249; Email: andreamorrone@jefferson.edu

The growth factor proepithelin functions as an important regulator of proliferation and motility. Proepithelin is overexpressed in a great variety of cancer cell lines and clinical specimens of breast, ovarian and renal cancer, as well as glioblastomas. Using recombinant proepithelin on 5637 transitional cell carcinoma-derived cells, we have shown previously that proepithelin plays a critical role in bladder cancer by promoting motility of bladder cancer cells. In this study, we used the ONCOMINE database and gene microarray analysis tool to analyze proepithelin expression in several bladder cancer microarray studies. We found a statistically significant increase in proepithelin messenger RNA expression in bladder cancers vis-à-vis non-neoplastic tissues, and this was associated with pathologic and prognostic parameters. Targeted downregulation of proepithelin in T24 transitional carcinoma cells with small hairpin RNA inhibited both Akt and mitogen-activated protein kinase pathways, severely reduced the ability of T24 cells to proliferate in the absence of serum and inhibited migration, invasion and wound healing. In support of these in vitro results, we discovered that proepithelin expression was significantly upregulated in invasive bladder cancer tissues compared with normal urothelium. In addition, proepithelin was secreted in the urine, where it was detectable by immunoblotting and enzyme-linked immunosorbent assay. Collectively, these results support the hypothesis that proepithelin may play a critical role as an autocrine growth factor in the establishment and progression of bladder cancer and suggest that proepithelin may prove a novel biomarker for the diagnosis and prognosis of bladder neoplasms.

Introduction

Proepithelin, also known as PC cell-derived growth factor, granulin–epithelin precursor, GP88, progranulin or acrogranin, is a growth factor that plays a critical role in development, cell cycle progression, cell motility and tumorigenesis (1). Proepithelin, originally isolated from different sources by several independent laboratories (2–5), is translated as a 593 amino acid proprotein with a predicted molecular weight of ~68 kDa, but due to its high degree of glycosylation, it is typically secreted as a ~90 kDa protein (4, 6). The precursor protein has a secretory signal peptide and 7½ cystein-rich 6 kDa tandem repeats (1).

Proepithelin undergoes elastase-mediated proteolytic processing (4) with the liberation of small, ~6 kDa peptides, which retain biological activity but usually exert opposite biological function compared with the precursor protein (7). The secretory leukocyte protease inhibitor counteracts this proteolysis by either direct binding to elastase or by sequestering epithelin peptides from the enzyme (4).

A vast body of evidence has now established that proepithelin plays a critical role in tumorigenesis (1). In several breast cancer cell lines, proepithelin expression correlates with an aggressive phenotype (8,9) and immunoneutralization of proepithelin inhibits estrogen-mediated proliferation of MCF-7 cells (10). Block of proepithelin expression by antisense strategy inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468 (9). In SW13 carcinoma cells, proepithelin-dependent activation of the phosphatidylinositol 3- kinase and mitogen-activated protein kinase (MAPK) pathways protects cells from anoikis, confers anchorage-independent growth and promotes tumor formation in nude mice (11).

Moreover, high proepithelin expression plays also a significant role in adipocytic teratoma, glioblastomas, multiple myeloma and renal cell, gastric and ovarian carcinomas (1,12–17). Recently, our laboratory has shown that recombinant proepithelin promotes migration, wound healing and invasion of 5637 bladder cancer cells, supporting the evidence that proepithelin may play as well a critical role in bladder cancer (6). Proepithelin is expressed in bladder cancer cells suggesting that endogenous proepithelin might also contribute in an autocrine fashion to these processes.

In this study, we used the ONCOMINE database and gene microarray analysis tool to analyze proepithelin expression in available bladder cancer microarray studies. In several independent data sets, we found a statistically significant increase in proepithelin messenger RNA (mRNA) expression in bladder cancers compared with non-neoplastic tissues. Significantly, proepithelin overexpression correlated with pathologic and prognostic parameters.

We confirmed that endogenous proepithelin expression contributes to the transforming phenotype of bladder cancer cells by targeting endogenous proepithelin in T24 transitional cell carcinoma-derived cells by shRNA approaches. Stable proepithelin depletion was associated with a severe reduction of the activation of the Akt and MAPK pathways, inhibited the ability of T24 cells to proliferate in the absence of serum and impaired motility of these cells. Immunohistochemical staining revealed that proepithelin expression was significantly higher in invasive bladder tumors as compared with normal bladder tissues. Furthermore, proepithelin was detectable in the urine by both immunoblotting and enzyme-linked immunosorbent assay (ELISA).

Collectively, these results support the hypothesis that proepithelin may play a critical role as an autocrine growth factor in the establishment and progression of bladder cancer and it may prove a novel clinical biomarker for diagnosis and prognosis in bladder tumors.

Materials and methods

Complementary DNA microarray analysis

The ONCOMINE database and gene microarray analysis tool, a repository for published complementary DNA microarray data (http://www.oncomine.org) (18,19), were explored (15 September 2008) for mRNA expression of proepithelin (progranulin or PC cell-derived growth factor) in non-neoplastic and bladder cancers. Statistical analysis of the differences in proepithelin expression between the aforementioned tissues was accomplished through use of ONCOMINE algorithms, which allow for multiple comparisons among different studies (18–20). Only studies with analysis results with P < 0.05 were considered.
Cell lines
Transitional cell carcinoma-derived human T24 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were maintained in RPMI medium supplemented with 10% fetal bovine serum. Serum-free medium (SFM) is Dulbecco’s modified Eagle’s medium supplemented with 0.1% bovine serum albumin and 50 µg/ml of transferrin (Sigma–Aldrich, St. Louis, MO).

Results

Proepithelin is overexpressed in bladder cancer

We have recently shown that human recombinant proepithelin promotes migration, wound healing and invasion of 5637 bladder cancer cells, supporting the evidence that proepithelin may play a critical role in bladder cancer (6). Proepithelin is expressed in bladder cancer cells (data not shown) suggesting that endogenous proepithelin may contribute in an autocrine fashion to the transforming phenotype.

In order to determine whether proepithelin is overexpressed in bladder cancer, we analyzed proepithelin expression in different publicly available bladder cancer microarray studies using the ONCOMINE database and gene microarray data analysis tool (18,19). The analysis evaluated proepithelin mRNA expression levels for each of the individual studies as well as performing a summary statistic, taking into account the significance of the gene expression across the considered studies. In two independent data sets (Figure 1A, classes A and B), there was a statistically significant increase of proepithelin mRNA expression levels in primary bladder cancers compared with non-neoplastic controls (P = 8 × 10^-8) (24,25). Significantly, proepithelin overexpression was associated with pathologic and prognostic parameters. Proepithelin mRNA levels were increased in high-grade compared with low-grade bladder cancer (class C) and in patients dead after 5 years of follow-up treatment compared with patients alive after 5 years of follow-up treatment (class D) (26). Proepithelin was also overexpressed in T1 versus Ta stage cancers (class E) (27).

Collectively, these results strongly suggest that proepithelin may play a critical role as an autocrine growth factor in the establishment and progression of bladder cancer.

Because T24 bladder cancer cells produce considerable levels of proepithelin and exhibit the ability to proliferate and migrate in the absence of serum, we determined whether endogenously produced proepithelin could contribute to the transforming phenotype of T24 cells. Therefore, we generated T24 cells stably expressing a 29mer shRNA construct targeting proepithelin. Mock-, vector- and shRNA proepithelin-transfected T24 cells were selected in medium containing puromycin and resistant cells were pooled and tested for proepithelin expression. Immunoblot analysis showed that shRNA proepithelin complementary DNA transfection significantly reduced proepithelin protein expression in T24 cells in both cell lysates and CM (Figure 1B), compared with parental and vector-transfected T24 cells. We also quantified the amount of proepithelin secreted in normal bladder stained with primary antibody after affinity depletion with blocking peptide (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, data not shown). An additional negative control was used by omitting the primary antibody and replacing it with preimmune serum.

Statistical analysis

Experiments were carried out in triplicate and repeated at least three times. Results are expressed as mean ± SD. All statistical analyses were carried out with SigmaStat for Windows version 3.10 (Systat Software, Port Richmond, CA). Results were compared by using the two-sided Student’s t-test. Differences were considered statistically significant at P < 0.05.

Cell growth and migration assays

Various T24 cells were plated in triplicate at a density of 3 × 10^4 cells per 35 mm plates in serum-supplemented medium. After 24 h, cells were washed three times in Dulbecco’s modified Eagle’s medium and transferred to SFM. Cells were counted after 24 and 48 h with a hemocytometer.

HTS FluoroBlok™ inserts (Becton Dickinson, Franklin Lakes, NJ) were saturated for 2 h at room temperature with phosphate-buffered saline−1% bovine serum albumin. After 24 h of starvation in SFM, cells were labeled with DiI (Molecular Probes, Invitrogen Corporation, Carlsbad, CA) for 20 min at 37°C and then seeded in the HTS FluoroBlok™ upper chamber and incubated at 37°C for 24 h. Migration was blocked by fixing the HTS FluoroBlok™ membranes in 4% paraformaldehyde. The HTS FluoroBlok™ membranes were mounted on a slide and migrated cells were counted and photographed with a Zeiss Axiovert 200M cell live microscope.

Wound healing and invasion assays

T24 cells were seeded onto 35 mm plates in serum-containing medium until subconfluence and then transferred to SFM. After 24 h, the plates were scratched with a thin disposable tip to generate a wound (500 μM) in the cells’ monolayer (6). Cells were analyzed and photographed after 3 and 6 h with a Zeiss Axiovert 200M cell live microscope using the Metamorph Image Acquisition and Analysis software (Universal Imaging, Ypsilanti, MI) at the Kimmel Cancer Center Flowcytometry Core Facility. Cell invasion through a three-dimensional (3D) extracellular matrix was assessed by a Matrigel™ invasion assay using BD Matrigel™ Invasion Chambers (BD Biocoat) with 8.0 μm filter membranes. Cells (5 × 10^5) in 200 μl of SFM were plated onto each filter and 750 μl of SFM placed in the lower chamber. After 24 h, filters were washed, fixed and stained with Coomassie brilliant blue. Cells on the upper surface of the filters were removed with cotton swabs. Cells that had invaded to the lower surface of the filter were counted under the microscope.

For 3D evasion assay (21), cells (5000 per drop) were included in Matrigel drops (6 mg/ml, Becton Dickinson). The drops were incubated for 3, 4 and 5 days in SFM or complete medium as control. Cell motility was analyzed by microscopy. Images were collected using a digital camera (Nikon Instruments Inc., Melville, NY) and cells outside each drop (five drops per cell line per experiment) were counted. The evasion ability was also determined by measuring the distance covered by the cells from the drop edges, after 5 days from inclusion. To perform this analysis, cells were stained with crystal violet and then pictures were taken. The distance covered was calculated by converting pixel to millimeters.

Immunohistochemical detection of proepithelin in normal and cancer bladder tissue specimens

Immunohistochemical analysis of proepithelin levels in bladder tissues was performed as described previously (23). Formalin-fixed, paraffin-embedded sections from five primary urothelial cell carcinomas were obtained from the Pathology Tissue Bank of Thomas Jefferson University and used to analyze the expression of proepithelin in normal and cancerous tissues. Informed consent to use excess pathological specimens for research purposes was obtained from all five patients. Slides were incubated overnight at room temperature with 1:100 dilution (100 ng/ml) of an anti-human monoclonal anti-proepithelin (PC cell-derived growth factor/GP88) antibody (A&G Pharmaceutical, Columbia, MD). We have previously tested the specificity of anti-proepithelin antibody in normal bladder stained with primary antibody after affinity depletion with blocking peptide (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, data not shown). An additional negative control was used by omitting the primary antibody and replacing it with preimmune serum.

Statistical analysis

Experiments were carried out in triplicate and repeated at least three times. Results are expressed as mean ± SD. All statistical analyses were carried out with SigmaStat for Windows version 3.10 (Systat Software, Port Richmond, CA). Results were compared by using the two-sided Student’s t-test. Differences were considered statistically significant at P < 0.05.

Results

Proepithelin is overexpressed in bladder cancer

We have recently shown that human recombinant proepithelin promotes migration, wound healing and invasion of 5637 bladder cancer cells, supporting the evidence that proepithelin may play a critical role in bladder cancer (6). Proepithelin is expressed in bladder cancer cells (data not shown) suggesting that endogenous proepithelin may contribute in an autocrine fashion to the transforming phenotype.

In order to determine whether proepithelin is overexpressed in bladder cancer, we analyzed proepithelin expression in different publicly available bladder cancer microarray studies using the ONCOMINE database and gene microarray data analysis tool (18,19). The analysis evaluated proepithelin mRNA expression levels for each of the individual studies as well as performing a summary statistic, taking into account the significance of the gene expression across the considered studies. In two independent data sets (Figure 1A, classes A and B), there was a statistically significant increase of proepithelin mRNA expression levels in primary bladder cancers compared with non-neoplastic controls (P = 8 × 10^-8) (24,25). Significantly, proepithelin overexpression was associated with pathologic and prognostic parameters. Proepithelin mRNA levels were increased in high-grade compared with low-grade bladder cancer (class C) and in patients dead after 5 years of follow-up treatment compared with patients alive after 5 years of follow-up treatment (class D) (26). Proepithelin was also overexpressed in T1 versus Ta stage cancers (class E) (27).

Collectively, these results strongly suggest that proepithelin may play a critical role as an autocrine growth factor in the establishment and progression of bladder cancer.

Because T24 bladder cancer cells produce considerable levels of proepithelin and exhibit the ability to proliferate and migrate in the absence of serum, we determined whether endogenously produced proepithelin could contribute to the transforming phenotype of T24 cells. Therefore, we generated T24 cells stably expressing a 29mer shRNA construct targeting proepithelin. Mock-, vector- and shRNA proepithelin-transfected T24 cells were selected in medium containing puromycin and resistant cells were pooled and tested for proepithelin expression. Immunoblot analysis showed that shRNA proepithelin complementary DNA transfection significantly reduced proepithelin protein expression in T24 cells in both cell lysates and CM (Figure 1B), compared with parental and vector-transfected T24 cells. We also quantified the amount of proepithelin secreted in the CM by an ELISA. Parental and vector-transfected T24 cells produced comparable amount of proepithelin, whereas shRNA-transfected T24 showed a 3-fold decrease in proepithelin secretion (Table I).

Proepithelin depletion induced a considerable reduction of cell proliferation in serum-deprived condition of T24 cells compared with parental and vector-transfected cells. We also quantified the amount of proepithelin secreted in the CM by an ELISA. Parental and vector-transfected T24 cells produced comparable amount of proepithelin, whereas shRNA-transfected T24 showed a 3-fold decrease in proepithelin secretion (Table I).

Proepithelin depletion induced a considerable reduction of cell proliferation in serum-deprived condition of T24 cells compared with parental and vector-transfected cells (Figure 1C). The ability of proepithelin-depleted T24 cells to grow was significantly restored at 48 h
Proepithelin is an autocrine growth factor for bladder cancer

The acquisition by cancer cells of an invasive phenotype is a critical step for tumor progression (28). Matrigel-coated filters are widely used to examine invasive migration through a 3D extracellular matrix (1,29). Proepithelin-depleted T24 cells showed a marked decrease in the ability to traverse Matrigel-coated filters after 48 h in the absence of serum as compared with parental and vector-transfected cells (Figure 2C).

We also determined the ability of T24 cells to evade from the extracellular matrix by measuring evasion from Matrigel drops (21). Downregulation of endogenous proepithelin significantly decreased the number of cells able to evade from the drop (Figure 3A and B). Moreover, the migration distance covered by T24/shPEP cells was markedly suppressed as compared with parental and V-control T24 cells (Figure 3C).

Collectively, our results suggest that endogenously produced proepithelin not only stimulates the migratory ability of urothelial cancer cells but also the cells’ ability to migrate through and from a complex 3D matrix such as Matrigel.

Proepithelin depletion inhibits the activation of the MAPK- and Akt-signaling pathways

Previous studies from our laboratory have shown that recombinant proepithelin induced the activation of the MAPK pathway in 5637 cells (second and fifth columns). At 48 h, SFM of proepithelin-depleted cells was also supplemented with 400 ng/ml of recombinant proepithelin (shPEP + PEP). *P < 0.05 compared with proepithelin-depleted T24 cells in SFM.
bladder cancer cells to stimulate cell motility but not proliferation of these cells (6). T24 cell proliferation and motility in the absence of serum are inhibited by proepithelin depletion, suggesting that the production of endogenous proepithelin may contribute in T24 cells to the activation of signaling pathways able to sustain both motility and cell proliferation.

In order to establish the signaling induced by endogenous proepithelin, we tested media conditioned by parental, pRS-transfected and shPEP-transfected T24 cells for their ability to activate Akt and MAPK pathways. We employed the PathScan Multiplex Western Cocktail I (Cell Signaling) that allows the testing of multiple pathways in one single blot. Serum-starved T24 cells were stimulated with the CM for 10 and 30 min. The medium conditioned from T24 and T24/pRS cells induced a prolonged activation of ERK1/2, with a concurrent, albeit less marked activation of p90RSK (the activation is more evident after longer exposures), one of ERK1/2 downstream effectors (6,30) (Figure 4A). Akt was activated as well, with the downstream activation of S6K (Figure 4A) as compared with unstimulated T24 cells. Significantly, CM from proepithelin-depleted T24 cells was severely impaired in the capacity of activating both the MAPK and Akt pathways (Figure 4A).

To confirm that the reduction in Akt and ERK1/2 activation in proepithelin-depleted T24 cells was specifically due to the loss of proepithelin, we stimulated T24/shPEP with recombinant proepithelin, which restored the ability of these cells to promote the activation of Akt and ERK1/2 (Figure 4B).

Together, these results strongly indicate that endogenous proepithelin contributes to the activation of both the Akt and MAPK pathways thereby promoting cell proliferation and motility.

Proepithelin is overexpressed in bladder cancer tissues and is secreted in the urine

Because proepithelin is overexpressed in several cancers (1) and the ONCOMINE analysis revealed that a statistically significant increase

| Table 1. Proepithelin levels in the various T24 cell lines |
|----------------|----------------|
| Cell line     | Proepithelin (ng/ml) |
| T24           | 360.8 ± 9.4      |
| T24/pRS       | 393.1 ± 52.3     |
| T24/shPEP     | 127.0 ± 25.8     |

Proepithelin levels were determined by ELISA in CM collected after 72 h incubation in SFM. Volumes were normalized on the number of cells. Data are the average of three independent experiments ± standard deviation.

![Fig. 2. Endogenous proepithelin promotes in vitro closure of a wound and invasion of T24 cells. (A) The in vitro wound healing motility assay in T24 cells in SFM was performed as described in Materials and Methods. Cells were analyzed with a cell live microscope using the Metamorph Image Acquisition and Analysis software (Universal Imaging) (×100). Ten fields per plate were examined. (B) For migration assay, T24 cells were seeded on FluoroBlocs and allowed to migrate for 24 h. Top, representative fields of migrated T24 cells (magnification, ×100); bottom, quantification of migrated T24 cells. The data are the average of three independent experiments run in duplicates ± standard deviation. (C) Quantification of invading T24 cells plated on Matrigel-coated FluoroBlocs and allowed to invade for 24 h. Data are expressed as invading cells per field. Mean ± SD of three independent experiments done in duplicate. *P < 0.01 versus T24 cells; †P < 0.01 versus vector-transfected T24 cells.](image)
in proepithelin expression in primary bladder cancers compared with non-neoplastic controls (Figure 1), we determined by immunohistochemical analysis the level of proepithelin expression in normal and bladder cancer sections. First, we established that proepithelin is present, although at low levels, in normal urothelial tissue (Figure 5A). Second, we discovered that proepithelin was expressed at considerably higher level in all five tumor bladder tissues analyzed (Figure 5A).

**Proepithelin is present in the urine**

The results presented above correlate well with our central hypothesis on the role of proepithelin in urinary pathology and further suggest that proepithelin might be secreted in the urine either through active secretion or after cell death, which often occurs in bladder cancer. Indeed, bladder cancers have a tendency to recur, necessitating close and regular follow-up. Therefore, there is a need for additional non-invasive and simple diagnostic tools with a high sensitivity and specificity for the detection of this cancer. Moreover, urothelial neoplasms may be related to the concentration of some growth factors such as the epidermal growth factor (31).

To evaluate proepithelin as a potential clinical marker of bladder cancer and correlate in future studies’ proepithelin urinary levels to disease severity, we needed to first determine whether proepithelin could be detected in the urine. We could detect proepithelin by immunoblotting in samples from concentrated urines obtained from non-cancerous patients, confirming the feasibility of the proposed approach (Figure 5B). Furthermore, we quantified proepithelin levels in the urine by ELISA (Figure 5C).

These results indicate that the combined analysis of proepithelin expression levels in urothelial tissues and urines may serve as a novel diagnostic and prognostic tool for bladder tumors.
Although bladder cancer is one of the most common malignancies in the USA (32), very little is known about the molecular mechanisms that determine transformation in the urothelium lining of the bladder wall. Most bladder cancers are characterized by frequent recurrences and often progress into an invasive phenotype, regardless of treatment with surgery, chemotherapy or immunotherapy. The present study provides the first evidence that the growth factor proepithelin contributes in an ‘autocrine’ fashion to bladder tumor formation and progression by promoting cell growth, migration and invasion of bladder cancer cells. Proepithelin may also prove as a novel clinical marker for the diagnosis and prognosis of bladder tumors.

Discussion

Fig. 4. Proepithelin depletion severely reduces the activation of the Akt and MAPK pathways. (A) CM from T24, T24/pRS and T24/shPEP cells was prepared as described (22). T24 cells were serum starved for 24 h and then stimulated with the CM for 10 and 30 min. The activation of p90RSK, Akt, ERK1/2 and S6 ribosomal protein was analyzed by western immunoblot using the PathScan Multiplex Western Cocktail 1 (Cell Signaling Technology). ElF4E protein is the control to monitor the loading of the samples. Blot is representative of three independent experiments. (B) Recombinant proepithelin restores Akt and ERK1/2 activation in T24/shPEP. T24/shPEP cells were serum starved for 24 h and then stimulated with 400 ng/ml of recombinant proepithelin for 10 and 30 min. The activation of Akt and ERK1/2 was analyzed by western immunoblot using the PathScan Multiplex Western Cocktail 1 (Cell Signaling Technology). Blot is representative of two independent experiments.

Fig. 5. Proepithelin detection in bladder cancer tissue specimens and urine samples. (A) Formalin-fixed, paraffin-embedded sections of non-malignant human bladder and bladder cancer tissue were deparaffinized in preparation for antigen retrieval by heating in a microwave oven for 10 min. Slides were cooled, rinsed and immunostained using a monoclonal antibody raised against human proepithelin (A&G Pharmaceutical) and visualized with an avidin–biotin method. From left to right: negative control normal urothelium stained with preimmune serum (x200), normal urothelium expressing proepithelin (x200), high levels of proepithelin are detected in invasive urothelial cancer (x400) and in area of squamous differentiation (x400). (B) Random and unidentified urine samples from normal individuals were pooled and then concentrated (10 ml ⇒ 200 µl) using Amicon Ultra Centrifugal Filter Devices at 4000 r.p.m. for 20 min (Millipore’s Corporate Headquarters, Billerica, MA, 10 K). Proepithelin levels were determined by immunoblot using anti-proepithelin polyclonal antibodies (Zymed Laboratories, Inc., South San Francisco, CA). Recombinant human proepithelin (300 ng) was loaded as control (PEP). Blot is representative of two independent experiments. (C) The amount of proepithelin present in urine was calculated by ELISA using a proepithelin ELISA kit (ALPCO Diagnostics).
Proepithelin is an autocrine growth factor for bladder cancer

(ii) Proepithelin mRNA levels correlate with prognostic parameters. (iii) Targeting endogenous proepithelin by shRNA approaches severely reduces the ability of T24 bladder cancer cells to proliferate in serum-deprived condition. (iv) Proepithelin depletion inhibits motility of T24 cells as determined by wound healing, migration, invasion and evasion assays. (v) The reduction of proepithelin expression inhibits the activation of the Akt and MAPK pathways. (vi) Proepithelin expression is significantly increased in bladder cancer specimens compared with normal tissue controls. (vii) Proepithelin is detectable by immunoblot analysis and can be measured by ELISA in urine samples.

We have recently established a role for proepithelin in bladder cancer by showing that recombinant proepithelin can effectively promote migration and invasion of 5637 cells at nanomolar amounts (6). Proepithelin was instead not strongly mitogenic for 5637 cells (6), suggesting that proepithelin in some cell systems may play a more critical role in promoting a stimulus for migration and invasion than for proliferation (11,33). Furthermore, in 5637 cells, proepithelin did not promote the activation of Akt, suggesting that the phosphatidylinositol 3'-kinase pathway does not play a role in migration and invasion in these cells. Because endogenously produced proepithelin in T24 cells activates both the Akt and MAPK pathways and promotes cell growth and motility, we conclude that proepithelin-evoked activation of these two signaling pathways might be required to promote not only cell motility but also cell proliferation of bladder cancer cells.

5637 cells responded in migration and invasion to the purified proepithelin precursor (6). Furthermore, we were able to detect only the 88 kDa proepithelin precursor by immunoblot on medium of T24 (Figure 1) and 5637 cancer cells (data not shown). These results would indicate that these cells secrete the proepithelin precursor protein, which is probably the bioactive form on bladder cancer cells. However, we cannot totally rule out the possibility that some intracellular processing into epithelin peptides may occur and contribute to the biological response in 5637 and T24 cells.

The ability of cancer cells to migrate and invade through the extracellular matrix is a critical step for tumor metastasis (28). Our results suggest that proepithelin, by promoting migration and invasion of bladder cancer cells, could help the transition from a non-invasive to an invasive phenotype in bladder cancers and perhaps in other solid tumors, where the role of proepithelin in promoting invasion and migration has been reported as well (11,29,34). Cell migration is also a fundamental aspect in numerous normal processes (28). Proepithelin expression is detectable in normal bladder urothelium (Figure 5) and promotes migration of primary cultures of normal urothelial cells (data not shown). Thus, our results would strongly suggest that proepithelin is not only important for migration of bladder cancer cells but may also play a physiological role in regulating cell migration of normal urothelial cells.

Because all the in vitro studies and the ONCOMINE analysis from several independent data sets pointed out the critical role of proepithelin as an autocrine growth factor for bladder cancer cells, we examined proepithelin expression in bladder cancer specimens by immunohistochemistry and determined that proepithelin is significantly overexpressed in invasive urothelial carcinomas compared with normal tissue. Furthermore, we have established that proepithelin as a precursor protein is detectable in urine samples where it can be quantified by ELISA.

Our present results together with previously published observations studies (6,35) suggest that the combined analysis of proepithelin levels in bladder cancer tissues and in urine from bladder cancer patients may have a diagnostic and prognostic value, especially in potentially identifying patients with increased risk of recurrence or aggressive behavior.

Taking into account the biological properties of proepithelin, it has been hypothesized that it could act through a ‘classic’ membrane receptor, as for the other known growth factors. However, to date a functional receptor has not been identified, although proepithelin (36) and epithelins (37) bind specifically to membrane proteins. Data from competitive binding experiments indicate that a long list of known growth factors and cytokines are unable to displace radiolabeled epithelin binding to its putative receptor (37) suggesting that the receptor for proepithelin is not a known tyrosine kinase receptor.

We are aware of the limitation of our previous and present studies based on cell lines and on a limited number of bladder cancer samples. Further, in vitro and in vivo experiments are required to fully elucidate proepithelin function in bladder cancer.

In conclusion, the identification of the growth factor proepithelin as a novel autocrine regulator of tumor cell motility and invasion could represent a novel molecular target for bladder cancer. Further characterization of proepithelin signaling could provide new leads for developing novel tumor biomarkers and for improved therapeutic approaches against bladder cancer.

Supplementary material

Supplementary Figure 1 can be found at http://carcin.oxfordjournals.org/

Funding

Benjamin Perkins Bladder Cancer Fund; Martin Greitzer Fund; National Institutes of Health (RO1 DK068419 to A.M., RO1 CA39481 and RO1 CA47282 to R.V.I.).

Acknowledgements

We would like to thank Judy Verdene for her skillful assistance with cell culture.

Conflict of Interest Statement: None declared.

References


Received December 3, 2008; revised January 28, 2009; accepted February 14, 2009